** Shares of drug developer Viking Therapeutics VKTX.O fall 8% to $30.82 premarket
** Co reported quarterly earnings in Wednesday, in which it also said its late-stage trial for the subcutaneous or under-the-skin version of experimental obesity drug VK2735 will start in Q2
** Investors were hoping for some meaningful developments, but the updates were mostly incremental, which sent shares lower - brokerage J.P.Morgan
** J.P.Morgan and another brokerage Oppenheimer say update was largely inline with expectations, although some investors were anticipating an earlier trial initiation
** Shares more than doubled in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。